OBJECTIVES:Functional dyspepsia is predominantly attributed to gastric sensorimotor dysfunctions. The contribution of intestinal chemosensitivity to symptoms is not understood. We evaluated symptoms and plasma hormones during enteral nutrient infusion and the association with impaired glucose tolerance and quality-of-life (QOL) scores in patients with functional dyspepsia vs. healthy controls. METHODS: Enteral hormonal responses and symptoms were measured during isocaloric and isovolumic dextrose and lipid infusions into the duodenum in 30 patients with functional dyspepsia (n=27) or nausea and vomiting (n=3) and 35 healthy controls. Infusions were administered in randomized order over 120 min each, with a 120-min washout. Cholecystokinin, glucose-dependent insulinotropic peptide, glucagon-like peptide 1 (GLP1), and peptide YY were measured during infusions. RESULTS: Moderate or more severe symptoms during lipid (4 controls vs. 14 patients) and dextrose (1 control vs. 12 patients) infusions were more prevalent in patients than controls (P≤0.01), associated with higher dyspepsia symptom score (P=0.01), worse QOL (P=0.01), and greater plasma hormone concentrations (e.g., GLP1 during lipid infusion). Moderate or more severe symptoms during enteral infusion explained 18%, and depression score explained 21%, of interpatient variation in QOL. Eight patients had impaired glucose tolerance, associated with greater plasma GLP1 and peptide YY concentrations during dextrose and lipid infusions, respectively. CONCLUSIONS: Increased sensitivity to enteral dextrose and lipid infusions was associated with greater plasma enteral hormone concentrations, more severe daily symptoms, and worse QOL in functional dyspepsia. These observations are consistent with the hypothesis that enteral hormones mediate increased intestinal sensitivity to nutrients in functional dyspepsia.
RCT Entities:
OBJECTIVES:Functional dyspepsia is predominantly attributed to gastric sensorimotor dysfunctions. The contribution of intestinal chemosensitivity to symptoms is not understood. We evaluated symptoms and plasma hormones during enteral nutrient infusion and the association with impaired glucose tolerance and quality-of-life (QOL) scores in patients with functional dyspepsia vs. healthy controls. METHODS: Enteral hormonal responses and symptoms were measured during isocaloric and isovolumic dextrose and lipid infusions into the duodenum in 30 patients with functional dyspepsia (n=27) or nausea and vomiting (n=3) and 35 healthy controls. Infusions were administered in randomized order over 120 min each, with a 120-min washout. Cholecystokinin, glucose-dependent insulinotropic peptide, glucagon-like peptide 1 (GLP1), and peptide YY were measured during infusions. RESULTS: Moderate or more severe symptoms during lipid (4 controls vs. 14 patients) and dextrose (1 control vs. 12 patients) infusions were more prevalent in patients than controls (P≤0.01), associated with higher dyspepsia symptom score (P=0.01), worse QOL (P=0.01), and greater plasma hormone concentrations (e.g., GLP1 during lipid infusion). Moderate or more severe symptoms during enteral infusion explained 18%, and depression score explained 21%, of interpatient variation in QOL. Eight patients had impaired glucose tolerance, associated with greater plasma GLP1 and peptide YY concentrations during dextrose and lipid infusions, respectively. CONCLUSIONS: Increased sensitivity to enteral dextrose and lipid infusions was associated with greater plasma enteral hormone concentrations, more severe daily symptoms, and worse QOL in functional dyspepsia. These observations are consistent with the hypothesis that enteral hormones mediate increased intestinal sensitivity to nutrients in functional dyspepsia.
Authors: T Edholm; M Degerblad; P Grybäck; L Hilsted; J J Holst; H Jacobsson; S Efendic; P T Schmidt; P M Hellström Journal: Neurogastroenterol Motil Date: 2010-11 Impact factor: 3.598
Authors: S S C Rao; M Camilleri; W L Hasler; A H Maurer; H P Parkman; R Saad; M S Scott; M Simren; E Soffer; L Szarka Journal: Neurogastroenterol Motil Date: 2011-01 Impact factor: 3.598
Authors: Amelia N Pilichiewicz; Penny Papadopoulos; Ixchel M Brennan; Tanya J Little; James H Meyer; Judith M Wishart; Michael Horowitz; Christine Feinle-Bisset Journal: Am J Physiol Regul Integr Comp Physiol Date: 2007-10-17 Impact factor: 3.619
Authors: Amelia N Pilichiewicz; Kate L Feltrin; Michael Horowitz; Gerald Holtmann; Judith M Wishart; Karen L Jones; Nicholas J Talley; Christine Feinle-Bisset Journal: Am J Gastroenterol Date: 2008-09-04 Impact factor: 10.864
Authors: Bradley Anderson; Paula Carlson; Marcello Laurenti; Adrian Vella; Michael Camilleri; Anshuman Desai; Kelly Feuerhak; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2019-11-05 Impact factor: 3.598
Authors: Melanie E Mabrey; Anna Beth Barton; Leonor Corsino; Susan B Freeman; Ellen D Davis; Elizabeth L Bell; Tracy L Setji Journal: Hosp Pract (1995) Date: 2015-03-06
Authors: Anshuman Desai; Phillip A Low; Michael Camilleri; Wolfgang Singer; Duane Burton; Subhankar Chakraborty; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2019-10-22 Impact factor: 3.598
Authors: Subhankar Chakraborty; Anshuman Desai; Magnus Halland; Duane Burton; Michael Camilleri; Alan R Zinsmeister; Adil E Bharucha Journal: Neurogastroenterol Motil Date: 2019-07-21 Impact factor: 3.598
Authors: Subhankar Chakraborty; Magnus Halland; Duane Burton; Anshuman Desai; Bridget Neja; Phillip Low; Wolfgang Singer; Michael Camilleri; Alan R Zinsmeister; Adil E Bharucha Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958